News

Hosted on MSN5mon
Blue Lake Biotechnology sees success in early RSV vaccine results
US-based clinical-stage intranasal vaccine company, Blue Lake Biotechnology’s pediatric nasal vaccine for respiratory syncytial virus (RSV), BLB201, was safe and effective for paediatric ...
Yahoo Finance6mon
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate
ATHENS, Ga. & SAN JOSE, Calif., November 25, 2024--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored ...
Morningstar2mon
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium
Morningstar brands and products Company Portfolio ...
WREG2y
Blue Lake Biotechnology Announces Positive Interim Phase 1 Data for BLB201 Intranasal RSV Vaccine
ATHENS, Ga. and LOS GATOS, Calif., Nov. 7, 2022 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing intranasal vaccines using a proprietary ...
Yahoo Finance7mon
Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress
ATHENS, Ga. & SAN JOSE, Calif., October 21, 2024--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored ...
Business Wire1y
Blue Lake Biotechnology Presenting at Upcoming BioFuture and BIO Investor Forum Conferences
ATHENS, Ga. & LOS GATOS, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company enlisting the full breadth of the immune system to protect people from ...
WREG2y
Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine
ATHENS, Ga. and LOS GATOS, Calif., July 21, 2022 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational ...